Longeveron Inc. (NASDAQ:LGVN) Q4 2022 Results Conference Call March 10, 2023 8:30 AM ET

Company Participants

James Clavijo - CFO

Wa’el Hashad - CEO

Dr. Chris Min - Chief Medical Officer

Conference Call Participants

Michael Okunewitch - Maxim Group

Operator

Good morning, and welcome to Longeveron's call today to discuss the company's 2022 Fourth Quarter and Full Year Financial Results. [Operator Instructions]

I would now like to turn the call over to James Clavijo, Longeveron's Chief Financial Officer. James, you may proceed.

James Clavijo

Thank you, operator. Good morning, everyone, and welcome to Longeveron's Fourth Quarter and Full Year 2022 Call. Today, we will provide a business update and discuss financial results for the fourth quarter and full year of 2022. Earlier this morning, we issued a press release with these results, which can be found under the Investors section of our website at www.longeveron.com. I am joined on the call today by the following members of Longeveron's management team: Mr. Wa’el Hashad, Chief Executive Officer; Dr. Chris Min, Chief Medical Officer; and Dr. Joshua Hare, Co-Founder, Chief Scientific Officer and Chairman. Mr. Hashad will begin with a brief corporate overview, Dr. Min will follow by a review of updates from Longeveron's clinical programs and Hypoplastic Left Heart Syndrome or HLHS, Alzheimer's disease and aging-related frailty, after which I will review our 2022 fourth quarter and full year financial results. Lastly, we will open the call for Q&A.

As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussions in our filings with the SEC, including our annual report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now I'd like to turn the call over to Mr. Wa’el Hashad, Chief Executive Officer of Longeveron. Wa’el?

Wa’el Hashad

Thank you, James. Good morning, everyone. Welcome to Longeveron Fourth Quarter and full 2022 business update and financial results. Thank you for joining us today. Longeveron is a clinical stage biotechnology company, developing regenerative medicine for unmet medical needs.

We had productive 2022 executing multiple key milestones and advancing our lead investigational product, Lomecel-B, across multiple indications. I am honored to have recently joined Longeveron as the Chief Executive Officer. I'm excited by the broad therapeutic potential of Lomecel-B and the great progress that has been made already to date.